Mavenir and Qualcomm Collaborate to Deliver Open RAN 4G/5G Indoor and Outdoor Radio Solutions for Public and Private Networks
24.6.2021 11:00:00 EEST | Business Wire | Press release
Mavenir1, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced a collaboration with Qualcomm Technologies, Inc. to develop indoor and outdoor solutions for both private and public network deployments aiming to broaden the choices for Open RAN customers.
With rising capacity and coverage demands of 5G, driven by diverse enterprise and consumer requirements, there is a growing need for network densification that harnesses all available spectrum based on flexible and cost-effective radio solutions. This collaboration aims to leverage the power of Mavenir’s software solutions and Qualcomm Technologies’ platform leadership, to deliver a suite of radio solutions based on Open RAN architecture.
Mavenir software running on the Qualcomm® 4G and 5G RAN Platforms for Small Cells (FSM), providing a full range of Open RAN software upgradable radio solutions is designed to meet the scalability demands of next-generation indoor and outdoor networks. This is made possible by architecture flexibility offered by Mavenir’s cloud-native solutions, and power-efficient design, and global spectrum band support offered by Qualcomm 4G and 5G RAN Platforms. The products aim to meet the needs for both Communications Service Provider (CSP) and Enterprise segments.
Key highlights include:
- The development and integration of Mavenir Open RAN split 2 compliant software solution with Qualcomm 4G and 5G RAN Platforms
- Mavenir Software solution adaptation across a variety of Qualcomm 4G and 5G RAN Platforms for Small Cells (FSM) based indoor and outdoor radio products developed by the Small Cell ODM ecosystem
“Mavenir’s role in growing the ecosystem has been to ensure that the market demand is being addressed with a range of radio options to fit all deployments and use cases,” said Mavenir’s Aniruddho Basu, SVP and GM of Emerging Business. “Mavenir’s containerized Open RAN, AI analytics and automation software, coupled with Qualcomm Technologies’ powerful 4G and 5G access point platforms aim to create an extensive range of high performance, cost-effective radio solutions for multiple segments and applications with full architectural flexibility.”
“The Qualcomm 5G RAN Platform for small cells, with support for 5G mmWave and Sub-6 GHz spectrum, is designed to deliver enhanced network coverage, capacity, and superior power efficiency,” said Gerardo Giaretta, Senior Director, Product Management, Qualcomm Technologies, Inc. “We are excited about this collaboration with an Open RAN industry leader like Mavenir as it will help drive open and virtualized 5G RAN proliferation globally in places like airports, stadiums, and hospitals."
1 Through its affiliate ip.access, a Mavenir Company
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm 4G and 5G RAN Platforms are products of Qualcomm Technologies, Inc. and/or its subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005039/en/
Contact information
Maryvonne Tubb
Mavenir
PR@mavenir.com
Loren Guertin
MatterNow
mavenir@matternow.com
Kevin Taylor
GlobalResultsPR
mavenir@globalresultspr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom